Murr M M, Balsiger B M, Farrugia G, Sarr M G
Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
J Surg Res. 1999 Jun 1;84(1):8-12. doi: 10.1006/jsre.1999.5590.
BACKGROUND: Inhibitory neurotransmission in the human intestine is poorly understood. This study was undertaken to determine the role of nitric oxide (NO), adenosine triphosphate (ATP), and vasoactive intestinal polypeptide (VIP) in inhibitory neurotransmission in human jejunal circular muscle strips. METHODS: In vitro response of precontracted (10(-5) M substance P) normal human jejunal muscle strips to electric field stimulation (EFS) under adrenergic and cholinergic receptor blockade was evaluated. Selective neural blockade was obtained by the NO synthase inhibitor l-NG-nitroarginine methyl ester (l-NAME, 10(-3) M), VIP receptor antagonist (4-Cl-d-Phe6Leu17-VIP, 10(-7) M), P2 purinergic receptor blocker suramin (3 x 10(14) M), or the calcium-dependent potassium channel blocker apamin (10(-6) M). Force generated in response to EFS was quantitated and analyzed statistically. RESULTS: Exogenous NO and ATP dose-dependently inhibited contractile activity and relaxed muscle strips with a concentration yielding a 50% effect (ED50) of 4.5 +/- 2.9 x 10(-6) M and 3.3 +/- 1.3 x 10(-4) M, respectively. EFS resulted in relaxation of precontracted muscle strips in all groups. When compared with controls, relaxation was decreased but not abolished by l-NAME (-0.12 +/- 0.03 vs -0.33 +/- 0. 05, -0.07 +/- 0.03 vs -0.34 +/- 0.05, and 0.04 +/- 0.03 vs -0.30 +/- 0.04 at 2, 5, and 10 Hz, respectively, P < 0.011). d-NAME (inactive stereoisomer of l-NAME), 4-Cl-d-Phe6Leu17-VIP, suramin, and apamin did not alter EFS-induced relaxation. CONCLUSIONS: Inhibition of NO synthesis by l-NAME reduced the inhibitory response to EFS, whereas blocking ATP and VIP receptors or other effector pathways had no effect. Our findings indicate that although NO plays a predominant role in inhibitory neurotransmission in human jejunal circular muscle, another neurotransmitter(s) appears to be involved as well. These data may impact on understanding mechanisms of disorders of gut dysmotility.
背景:人们对人类肠道中的抑制性神经传递了解甚少。本研究旨在确定一氧化氮(NO)、三磷酸腺苷(ATP)和血管活性肠肽(VIP)在人类空肠环形肌条抑制性神经传递中的作用。 方法:评估在肾上腺素能和胆碱能受体阻断下,预收缩(10⁻⁵ M 物质P)的正常人空肠肌条对电场刺激(EFS)的体外反应。通过一氧化氮合酶抑制剂L-NG-硝基精氨酸甲酯(L-NAME,10⁻³ M)、VIP受体拮抗剂(4-Cl-d-Phe⁶Leu¹⁷-VIP,10⁻⁷ M)、P2嘌呤能受体阻滞剂苏拉明(3×10⁻⁴ M)或钙依赖性钾通道阻滞剂蜂毒明肽(10⁻⁶ M)实现选择性神经阻断。对EFS产生的力进行定量并进行统计学分析。 结果:外源性NO和ATP剂量依赖性地抑制收缩活性并使肌条松弛,产生50%效应的浓度(ED50)分别为4.5±2.9×10⁻⁶ M和3.3±1.3×10⁻⁴ M。EFS导致所有组的预收缩肌条松弛。与对照组相比,L-NAME使松弛减弱但未消除(分别在2、5和10 Hz时为-0.12±0.03对-0.33±0.05、-0.07±0.03对-0.34±0.05、0.04±0.03对-0.30±0.04,P<0.011)。D-NAME(L-NAME的无活性立体异构体)、4-Cl-d-Phe⁶Leu¹⁷-VIP、苏拉明和蜂毒明肽未改变EFS诱导的松弛。 结论:L-NAME抑制NO合成降低了对EFS的抑制反应,而阻断ATP和VIP受体或其他效应途径则无作用。我们的研究结果表明,尽管NO在人类空肠环形肌的抑制性神经传递中起主要作用,但似乎也有其他神经递质参与。这些数据可能影响对肠道动力障碍机制的理解。
Br J Pharmacol. 2004-9
Am J Physiol Gastrointest Liver Physiol. 2016-8-1
Naunyn Schmiedebergs Arch Pharmacol. 2009-5
Pediatr Surg Int. 2008-12
Am J Physiol Gastrointest Liver Physiol. 2008-7
Br J Pharmacol. 2004-9
World J Gastroenterol. 2001-10